HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

References

• Macías J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50(4):1056–1063.10.1002/hep.23136
   PubMed Web of Science ®Google Scholar
• Lo Re V 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):69–79.
   Web of Science ®Google Scholar
• Monje-Agudo P, Castro-Iglesias A, Rivero-Juárez A, et al. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Eur J Clin Microbiol Infect Dis. 2015;34(10):1929–1936.10.1007/s10096-015-2434-6
   PubMed Web of Science ®Google Scholar
• Documento de consenso del Grupo Español para el Estudio de la Hepatitis (GEHEP) sobre el tratamiento de la hepatitis C. http://www.seimc.org/contenidos/gruposdeestudio/gehep/dcientificos/documentos/gehep-dc-2014-TratamientodelaHepatitisC_actualizacionJun2015.pdf. Accessed December 4, 2016.
   Google Scholar
• European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2015. http://www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf. Accessed December 4, 2016.
   Google Scholar
• Rockstroh JK. Does HIV remain a risk factor for achieving sustained virologic response under direct acting antiviral-based modern hepatitis C virus therapy? Clin Infect Dis. 2014;59(12):1777–1778.10.1093/cid/ciu662
   PubMed Web of Science ®Google Scholar
• Soriano V, Sherman KE, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS. 2011;25(18):2197–2208.10.1097/QAD.0b013e32834bbb90
   PubMed Web of Science ®Google Scholar
• Shafran D. HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: it’s time to end segregation and integrate HIV patients into HCV trials. Clin Infect Dis. 2015;61(7):1127–1134.10.1093/cid/civ438
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–1206.10.1056/NEJMoa1010494
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–2416.10.1056/NEJMoa1012912
   PubMed Web of Science ®Google Scholar
• Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV/hepatitis C virus–coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014(12);59:1768–1776.10.1093/cid/ciu659
   PubMed Web of Science ®Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132–142.e4.10.1053/j.gastro.2014.03.051
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad, Servicios Sociales e Igualdad. Therapeutic strategy for chronic hepatitis caused by hepatitis C virus in the National Health System: general recommendations and current treatment regimens. http://aeeh.es/wp-content/uploads/2015/04/a77478e2a1147600cb9979b5992281cb.pdf. Accessed December 4, 2016.
   Google Scholar
• Neukam K, Munteanu DI, Rivero-Juárez A, et al. Boceprevir or telaprevir based triple therapy against chronic hepatitis C in HIV coinfection: real-life safety and efficacy. PLoS One. 2015;10(4):e0125080.10.1371/journal.pone.0125080
   PubMed Web of Science ®Google Scholar
• Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13(3):372–374.10.1016/0168-8278(91)90084-O
   PubMed Web of Science ®Google Scholar
• Martel-Laferrière V, Brinkley S, Bichoupan K, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med. 2014;15(2):108–115.10.1111/hiv.2014.15.issue-2
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med;373(8):705–713.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–725.10.1056/NEJMoa1503153
   PubMed Web of Science ®Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232–1239.10.1001/jama.2015.1373
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–1231.10.1001/jama.2015.1328
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014(16);370:1483–1493.10.1056/NEJMoa1316366
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.10.1056/NEJMoa1402454
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrosis. N Engl J Med. 2014;370(21):1973–1982.10.1056/NEJMoa1402869
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–1097.10.1016/S0140-6736(14)61793-1
   PubMed Web of Science ®Google Scholar
• Milazzo L, Lai A, Calvi E, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 2016; doi:10.1111/hiv.12429. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Goeser F, Glässner A, Kokordelis P, et al. HIV mono-infection is associated with an impaired anti-HCV activity of NK cells. AIDS. 2016;30(3):355–363.
   PubMed Web of Science ®Google Scholar
• Kowdley K, Gordon SC, Reddy KJ, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.10.1056/NEJMoa1402355
   PubMed Web of Science ®Google Scholar
• Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016;64(2):301–307.10.1016/j.jhep.2015.10.005
   PubMed Web of Science ®Google Scholar
• Recommendations for testing, managing, and treating hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. January 2014 http://www.hcvguidelines.org/. Accessed December 4, 2016.
   Google Scholar
• Pineda JA, Núñez-Torres R, Téllez F, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect. 2015;71(5):571–577.10.1016/j.jinf.2015.07.006
   PubMed Web of Science ®Google Scholar